Oxaliplatin Gry

Oxaliplatin, the active ingredient in Oxaliplatin Gry, is a platinum compound presented as a injection for intravenous use. It treats colorectal cancer and other gastrointestinal malignancies in adult patients. GNH USA supplies Oxaliplatin Gry as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Oxaliplatin Gry as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin is employed in chemotherapy regimens targeting cancers of the gastrointestinal tract.

- Colorectal cancer: enhances tumor response when combined with fluoropyrimidines and leucovorin. - Gastric cancer: contributes to tumor shrinkage in combination protocols. - Pancreatic cancer: used as part of multi‑drug regimens to improve disease control. - Esophageal cancer: added to standard chemotherapy to increase response rates. - Appendiceal cancer: incorporated in systemic therapy for advanced disease. - Peritoneal carcinomatosis: applied in regional perfusion techniques to reduce tumor burden.

Oxaliplatin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Diarrhea: loose stools that may require supportive care. - Fatigue: generalized tiredness during treatment cycles. - Myelosuppression: reduced blood cell counts, increasing infection risk. - Elevated liver enzymes: transient changes in hepatic function tests.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis or bronchospasm. - Acute neurotoxicity: sudden onset of muscle cramps or spasms. - Hemolytic anemia: destruction of red blood cells. - Thrombotic events: blood clot formation in veins or arteries. - Renal impairment: decreased kidney function requiring monitoring. - Cardiotoxicity: rare heart rhythm disturbances.

When using Oxaliplatin, clinicians should observe several safety measures to minimize risks.

- Renal function: assess baseline creatinine and monitor during therapy. - Hepatic function: evaluate liver enzymes before each cycle. - Neuropathy monitoring: conduct regular neurological assessments. - Hematologic monitoring: perform complete blood counts frequently. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risk. - Store at below 25°C: keep in original packaging, protect from moisture and light.

Oxaliplatin may interact with other agents, requiring careful management.

Major Interactions (Avoid): - Nephrotoxic drugs: concurrent use can worsen kidney injury. - Highly protein‑bound agents: may displace oxaliplatin, increasing toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants: heightened bleeding risk, monitor coagulation parameters. - Antiemetics: potential additive central nervous system effects. - CYP450 modulators: may alter plasma levels of co‑administered drugs. - Radiotherapy: combined neurotoxicity risk, especially peripheral neuropathy. - Immunosuppressants: increased infection susceptibility, require vigilance.